Biogen Inc. Common Stock (BIIB) Valuation
Historical valuation analysis based on 1279 data points (2021-09-13 to 2026-10-16)
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and con...
Biogen Inc. Common Stock (BIIB) currently trades at a P/E ratio of 41.19 (historical range: 11.24–41.67, median: 19.45), placing it at the 100th percentile — expensive relative to its history, P/S ratio of 3.43 (range: 1.69–4.57, 69th percentile — above its historical average), EV/EBITDA of 19.13 (range: 3.86–29.85, 79th percentile).
Biogen Inc. Common Stock trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 41.19 | 19.45 | 100th | expensive relative to its history |
| P/S Ratio | 3.43 | 3.03 | 69th | above its historical average |
| EV/EBITDA | 19.13 | 9.33 | 79th | above its historical average |
| FCF Yield | 7.84% | 7.05% | 53th | near its historical average |
Biogen Inc. Common Stock (BIIB) Valuation & P/E History
Biogen Inc. Common Stock (BIIB) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry currently trading at $232.65 with a market capitalization of $34.4 billion. This page provides historical valuation analysis for BIIB based on 1279 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 41.19 is above the historical median of 19.45, placing BIIB at the 100th percentile of its valuation range. The P/S ratio of 3.43 compares to a median of 3.03.
BIIB Valuation Metrics & Historical Range
The valuation table above shows Biogen Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BIIB is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BIIB is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Biogen Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BIIB Overvalued or Undervalued?
Biogen Inc. Common Stock trades well above its own historical valuation range across most metrics. The overall valuation percentile of 83 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BIIB is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BIIB analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BIIB trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.